Aligos Therapeutics, Inc. (ALGS) Q4 2024 Annual Earnings
ALGS·Reported March 10, 2025·Before market open
Aligos Therapeutics, Inc. reported Q4 2024 revenue of $629.0K, beat analyst consensus of $500.0K by $129.0K. Diluted EPS came in at $-3.41, missed the $-2.63 consensus by $0.78.
Revenue
$629.0Kbeat by $129.0K
Consensus: $500.0KDiluted EPS
$-3.41missed by $0.78
Consensus: $-2.63
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Aligos Therapeutics, Inc.'s Q4 2024 earnings report.
Aligos Therapeutics, Inc. (ALGS) reported Q4 2024 earnings on March 10, 2025 before market open.
Aligos Therapeutics, Inc. reported revenue of $629.0K and diluted EPS of $-3.41 for Q4 2024.
Revenue beat the consensus estimate of $500.0K by $129.0K. EPS missed the consensus estimate of $-2.63 by $0.78.
You can read the 10-K periodic report (0000950170-25-035929) directly on SEC EDGAR. The filing index links above go to sec.gov.